ClinicalTrials.gg
CompletedNCT05569239Updated Oct 16, 2026

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

A Phase 2 interventional study of OVX836 480µg and Saline Solution in Influenza, sponsored by Osivax. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Osivax · Phase 2, Interventional, and Prevention

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2,891
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Influenza, Human with a site in Finland — 3 open to participants now, 3 under way, 1 of them phase 3. Influenza, Human · Finland.

Enrollment
16th of 37
2,891 · median 807
Started
2025
with 1 other
Phase 2
8 of 43
none open now
Registered
38th of 43
by date

Among the 43 studies in Influenza, Human with a site in Finland, this one is the 16th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 38th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 43 studies in Influenza, Human with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Influenza, Human with a site in Finland, or all of them as a file.
02

Study summary

The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.

Read the detailed description

This Phase 2b proof-of-concept field efficacy study is designed as a randomized, double-blind, parallel groups, placebo-controlled, multi-country, multicenter clinical trial. This design of prospective interventional trial is the gold standard in evaluating absolute efficacy of a product in preventing a disease or an outcome. An adequate number of observations is ensured by the multicenter approach.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Healthy male or female subjects, as determined by medical history and medical examination.
  3. Between the ages of 18 and 59 years, inclusive.
  4. Subject socially active: living in a family with children or with other house-hold members, having frequent social contacts at university, work, in public places such as restaurants, theaters, public transportation, etc.
  5. Subjects compliant with the reproductive criteria for male and female participants .
  6. Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures
  7. Able to read, understand and complete an electronic Diary and electronic Patient Reported Outcome.
  8. Able to read and sign the subject information sheet and informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with an authorized or experimental seasonal, zoonotic or pandemic influenza vaccine within 6 months before the day of vaccination or planned to receive it during the whole study period.
  2. Formal indication for influenza vaccination on an individual basis according to local recommendations, for example based on occupational risk, or underlying medical conditions. An informed subject who would refuse to get the regular influenza vaccination would be allowed to participate in this study.
  3. Any known or suspected immunodeficient conditions.
  4. Past or current history of significant diseases, as judged by the Investigator.
  5. Known or suspected infection with , virus, or virus.
  6. Current history of significant uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases, as judged by the Investigator.
  7. Planned absences without access to the site, i.e. vacation or business trips, for more than 7 consecutive days during the study period
  8. Pregnant or lactating woman.
  9. Females planning to become pregnant or planning to discontinue precautions until the end of the trial.
  10. Having received another vaccine within 1 month prior to the day of study vaccination, except COVID-19 vaccines for which the minimum time period should be two weeks prior to study vaccination.
  11. Having participated or currently participating in an OVX836 study or in the OVX-FLU-002 study.
  12. Planning to receive any other vaccines during the first 28 days following the study vaccine administration, except COVID-19 vaccines which can be administered from 14 days following the study vaccine administration.
  13. Administration of any investigational or non-registered drug or vaccine within 1 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period.
  14. History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period.
  15. Presence of an acute febrile illness on the day of planned vaccination (oral temperature >38.0°C; temporary exclusion criterion).

16Diagnosed long COVID-19 subjects. 17. Presence of a condition in the ear-nose-throat area, such as nasal septum deviation, atrophic rhinitis, etc…, that could render nasal and nasopharyngeal swabs more difficult to perform, or increase the risk of bleeding; to be confirmed by medical history question and inspection of nasal passage.

18. Past or current history of any progressive or severe uncontrolled neurological disorder, seizure disorder or Guillain-Barré syndrome.

19. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.

20. Past (stopped less than 6 months before enrolment) or current smoking habit above 10 cigarettes per day.

21. Past (stopped less than 6 months before enrolment) or current history of heavy alcohol use, defined as follows: for men, consumption of more than 4 standard drinks on any day or more than 14 standard drinks per week, and for women, consumption of more than 3 standard drinks on any day or more than 7 standard drinks per week.

22. Past (stopped less than 6 months before enrolment) or current use of recreational drugs, which could interfere with the adherence to the protocol procedures.

23. Chronic or prolonged treatment (>10 consecutive days) that can affect immune response, such as systemic (≥ 20 mg/day prednisone or equivalent or dexamethasone >4 mg/day), high dose inhaled (>800 μg/day beclomethasone or equivalent; occasional inhaled, topical or localized injections [intra-articular or intra-bursal] of corticosteroids for asthma therapy are allowed), or immunomodulators/suppressors (certain monoclonal antibodies can be approved on a case by case basis) within 28 days before study entry or during the whole study duration.

24. Chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, acetylsalicylic acid, or paracetamol within 7 days before study entry and up to 28 days post-vaccination.

25. Prophylactic or therapeutic use of influenza antivirals within 7 days prior to the day of study vaccination or during the whole study duration.

26. History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin or any other component of the OVX836 vaccine.

27. Any to intramuscular administration, as judged by the Investigator.

28. Presence of extended tattoos on both deltoid muscles. 29. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study, or pose additional risk to the subjects due to participation in the study, either directly or through any treatments administered for that illness.

30. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse (or assimilated), parent, child or sibling, whether biological or legally adopted.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,891 participants (actual)

Study arms

  • Experimental
    OVX836 480µg

    Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein in the influenza virus. One single administration intramuscularly of 480µg dose on Day1.

    Biological: OVX836 480µg

  • Placebo comparator
    Placebo

    Saline solution (B. Braun Ecoflac Plus) Saline solution (Nacl 0.9%), B. Braun Ecoflac Plus 50mL. One single administration intramuscularly of a 0.8mL dose on Day1.

    Biological: Saline Solution

Interventions

  • BiologicalOVX836Studies of OVX836OVX836 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One single administration intramuscularly at Day 1.

  • BiologicalSaline Solution

    One single administration intramuscularly at Day 1.

06

What researchers measure

Primary outcomes

  1. First occurrence of RT-PCR-confirmed influenza Type A symptomatic disease

    Time frame: During the whole study duration, up to maximum 10 months

Secondary outcomes

  1. First occurrence of RT-PCR-confirmed influenza symptomatic disease irrespective of strain/type.

    Time frame: During the whole study duration, up to maximum 10 months.

  2. First of occurrence of RT-PCR-confirmed influenza Type B symptomatic disease

    Time frame: During the whole study duration, up to maximum 10 months

  3. Number of subtype of virus in RT-PCR-confirmed influenza Type A cases.

    Time frame: During the whole study duration, up to maximum 10 months

  4. Severity and duration of Influenza Like Illness episodes

    Time frame: During the whole study duration, up to maximum 10 months

  5. First occurence of clinical influenza-like disease irrespective of causal agent

    Time frame: During the whole study duration, up to maximum 10 months

  6. Number of occurence of solicited local and systemic signs and symptoms

    Time frame: During 7 days after vaccine administration

  7. Number of occurence of subjects reporting unsolicited AEs

    Time frame: During 29 days after vaccine administration

  8. Number of occurence of subjects reporting Serious Adverse Events, Adverse Events of Special Interest, New Onset of Chronic Disease, Medical Attended Adverse Events

    Time frame: During the whole study period, maximum 10 months

  9. Cell-mediated immune response in Peripheral Blood Mononuclear Cells, measured by Interferon Gamma Enzyme-Linked Immunospot Assay in a limited subset of 56 subjects.

    Elispot

    Time frame: At Day 1 and Day 8

  10. Number and percentage of subjects with NP-specific T-cell measured by Interferon Gamma Enzyme-Linked Immunospot Assay.

    Elispot

    Time frame: At Day 1 and Day 8

  11. Percentage of NP specific CD4+ and CD8+ T-cell measured by flow cytometry on PBMCs as expressing IL-2, TNFα and/or IFNγ at pre-injection baseline (Day 1)

    ICS

    Time frame: At Day 1 and Day 8

  12. Number and percentage of subjects with a percentage of NP specific CD4+ and CD8+ T-cell expressing IL-2, TNFα and/or IFNγ at Day 8 or Day 29 higher than the percentile 95 of the pre-injection baseline (Day 1)

    ICS

    Time frame: At Day 1 and Day 8

  13. Geometric Mean Titer of anti-Nucleoprotein immunoglobulin G (Enzyme-Linked Immunosorbent Assay, serum).

    Elisa

    Time frame: At Day 1 and Day 8

  14. Number and percentage of subjects with a four-fold increase of anti-Nucleoprotein immunoglobulin G (Enzyme-Linked Immunosorbent Assay, serum) titre with respect to pre-injection baseline (Day 1)

    Elisa

    Time frame: At Day 1 and Day 8

  15. Percentage of NP specific CD4+ and CD8+ T-cell measured by flow cytometry on PBMCs as expressing IL-2, TNFα and/or IFNγ in a limited subset of 56 subjects

    ICS

    Time frame: At Day 1 and Day 8

  16. Anti-Nucleoprotein immunoglobulin G measured by Enzyme-Linked Immunosorbent Assay in, serum in a limited subset of 56 subjects.

    Elisa

    Time frame: At Day 1 and Day 8

07

Study locations

16 sites
  • Site BE-02
    Antwerp, Belgium
  • Site BE-03
    Antwerp, Belgium
  • Site BE-01
    Ghent, Belgium
  • Site BE-04
    Mechelen, Belgium
  • Site FI-12
    Espoo, Finland
  • Site FI-08
    Helsinki, Finland
  • Site FI-13
    Jarvenpaa, Finland
  • FI-14
    Kokkola, Finland
  • Site FI-11
    Oulu, Finland
  • Site FI-15
    Seinäjoki, Finland
  • Site FI-09
    Tampere, Finland
  • Site FI-10
    Turku, Finland
  • Site FR-05
    Lyon, France
  • Site FR-07
    Paris, France
  • Site FR-06
    Rennes, France
  • Site DE-16
    München, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 8 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 6, 2022
StartActual
Sep 8, 2025
Primary completionActual
May 18, 2026
CompletionActual
May 18, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Primary completion
May 29, 2026→May 18, 2026 (actual)
Oct 16, 2026
Study completion
May 29, 2026→May 18, 2026 (actual)
Oct 16, 2026
Enrollment
2850 (estimated)→2891 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Primary completion May 29, 2026→May 18, 2026 (now actual)
    Study completion May 29, 2026→May 18, 2026 (now actual)
    Enrollment 2850 (estimated)→2891 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05569239
Lead sponsor
Osivax
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Sep 8, 2025
Primary completion
May 18, 2026
Completion
May 18, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OVX836

Start the discussion